- UroToday Home
- Urologic Oncology
Prostate Cancer Abstracts and Beyond
Recent Abstracts
-
ADT combinations with radiation for prostate cancer: A systematic review and meta-analysis.Prostate CancerJuly 21, 2026
-
CALB2 is a Mechanoresistance Gene in Metastatic Prostate Cancer.Prostate CancerJuly 21, 2026
-
Global research trends and hotspots in robotic-assisted prostate biopsy: a bibliometric analysis from 2008 to 2026.Prostate CancerJuly 21, 2026
-
Genomic Classification to Predict Survival in Metastatic Prostate Cancer: Development of Somatic Tumor Risk Assessment for Overall Survival-Prostate.Prostate CancerJuly 21, 2026
-
EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2026 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent.Prostate CancerJuly 21, 2026
-
EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2026 Update: Treatment of Relapsing and Metastatic Prostate Cancer.Prostate CancerJuly 21, 2026
-
Structured robotic surgery training in Germany: a five-year evaluation of the German curriculum for robot-assisted radical prostatectomy.Prostate CancerJuly 21, 2026
-
Emerging antibody-drug conjugates in metastatic castration-resistant prostate cancer.Prostate CancerJuly 20, 2026
-
PI-RADS-stratified MRI-based PSA Density for Predicting Adverse Pathology after Robotic-assisted Laparoscopic Radical Prostatectomy.Prostate CancerJuly 20, 2026
-
Long-term oncologic outcomes of patients with grade group 1 prostate cancer and pT3a disease on final pathology.Prostate CancerJuly 20, 2026
Beyond the Abstracts
-
Imaging Features That Predict Indeterminate Bone Lesion Outcomes on 18F-DCFPyL PSMA PET/CT Scan: A Multicenter Cohort of 42 Biopsy-Proven Lesions - Beyond the AbstractProstate CancerJuly 21, 2026
-
SBRT plus Abiraterone Acetate and ADT versus Abiraterone Acetate and ADT in Oligometastatic Castrate-Resistant Prostate Cancer (ARTO): Long-Term, Unplanned Overall Survival Analysis of an Open-Label, Randomised, Phase 2 Trial - Beyond the AbstractProstate CancerJuly 20, 2026
-
Robust Meta-Analysis of a Clinical Cell-Cycle Risk (CCR) Score Demonstrates Broadly Applicable Metastasis and Disease-Specific Mortality Risk Stratification in Men With Localized Prostate Cancer - Beyond the AbstractProstate CancerJuly 20, 2026
-
The Predictive Role of [177Lu]Lu-PSMA-617 SPECT/CT Semiquantitative Parameters from the 1st RLT Cycle in Advanced mCRPC: A Preliminary Bicentric Lesion-Based Analysis - Beyond the AbstractProstate CancerJuly 17, 2026
-
The Evolving PI-RADS Paradigm - Beyond the AbstractProstate CancerJuly 17, 2026
-
Same Target, Different Tools: A Multicenter Comparison of Local Anesthesia Cognitive Fusion, General Anesthesia Fusion, and General Anesthesia Grid Prostate Biopsy - Beyond the AbstractProstate CancerJuly 16, 2026
-
Intrafraction Motion Mitigation by Rectal Spacers in Prostate SBRT: Balloon, Hydrogel, and No-Spacer Comparison - Beyond the AbstractProstate CancerJuly 9, 2026
-
Clinical Trial Protocol for ProBio-mHSPC: A ctDNA-driven De-escalation and Intensification Platform Trial for Metastatic Hormone-sensitive Prostate Cancer - Beyond the AbstractProstate CancerJuly 2, 2026
-
Focal Cryo-ablation for Treatment of Intermediate Favorable Risk (Grade Group 2) Prostate Cancer - Beyond the AbstractProstate CancerJuly 2, 2026
-
Quantifying the Renal Impact of [177Lu]Lu-PSMA-617: A Longitudinal Analysis of Real-World Data from the LUMEN Registry - Beyond the AbstractProstate CancerJune 25, 2026